[go: up one dir, main page]

WO2006014669A3 - Methods and compositions for treatment of intraepithelial neoplasia - Google Patents

Methods and compositions for treatment of intraepithelial neoplasia Download PDF

Info

Publication number
WO2006014669A3
WO2006014669A3 PCT/US2005/025639 US2005025639W WO2006014669A3 WO 2006014669 A3 WO2006014669 A3 WO 2006014669A3 US 2005025639 W US2005025639 W US 2005025639W WO 2006014669 A3 WO2006014669 A3 WO 2006014669A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
intraepithelial neoplasia
intraepithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/025639
Other languages
French (fr)
Other versions
WO2006014669A2 (en
Inventor
Neil Frazer
Jonathan Heller
Rocio Lopez
Melissa Rhodes
Ru Chih C Huang
Richard Dalby
Niharika Khanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Maryland Baltimore
Erimos Pharmaceuticals LLC
University of Maryland College Park
Original Assignee
Johns Hopkins University
University of Maryland Baltimore
Erimos Pharmaceuticals LLC
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, University of Maryland Baltimore, Erimos Pharmaceuticals LLC, University of Maryland College Park filed Critical Johns Hopkins University
Priority to US11/572,349 priority Critical patent/US8440648B2/en
Publication of WO2006014669A2 publication Critical patent/WO2006014669A2/en
Publication of WO2006014669A3 publication Critical patent/WO2006014669A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.
PCT/US2005/025639 2004-07-20 2005-07-19 Methods and compositions for treatment of intraepithelial neoplasia Ceased WO2006014669A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/572,349 US8440648B2 (en) 2004-07-20 2005-07-19 Methods and compositions for treatment of intraepithelial neoplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58941804P 2004-07-20 2004-07-20
US60/589,418 2004-07-20

Publications (2)

Publication Number Publication Date
WO2006014669A2 WO2006014669A2 (en) 2006-02-09
WO2006014669A3 true WO2006014669A3 (en) 2006-11-02

Family

ID=35787691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025639 Ceased WO2006014669A2 (en) 2004-07-20 2005-07-19 Methods and compositions for treatment of intraepithelial neoplasia

Country Status (1)

Country Link
WO (1) WO2006014669A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294432A1 (en) * 2004-10-06 2006-04-20 Chih-Chuan Chang Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US5541232A (en) * 1993-06-23 1996-07-30 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases
US6417234B1 (en) * 1999-10-15 2002-07-09 Johns Hopkins University Nordihydroguaiaretic derivatives for use in treatment of tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US5541232A (en) * 1993-06-23 1996-07-30 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases
US6417234B1 (en) * 1999-10-15 2002-07-09 Johns Hopkins University Nordihydroguaiaretic derivatives for use in treatment of tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HELLER ET AL.: "Tetra-O-methyl Nordihydroguaiaretic Acid Induces G2 Arrest in Mammalian Cells and Exhibits Tumoricidal Activity in Vivo", CANCER RESEARCH, vol. 61, 15 July 2001 (2001-07-15), pages 5499 - 5504, XP002322391 *
PARK S. ET AL.: "Inhibition of fos-jun-DNA complex formation by dihydroguaiaretic acid and in vitro cytotoxic effects on cancer cells", CANCER LETTERS, vol. 127, 1998, pages 23 - 28, XP003003599 *

Also Published As

Publication number Publication date
WO2006014669A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2008042216A3 (en) Methods, kits, and compositions for generating new hair follicles and growing hair
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2007073497A3 (en) Calcium channel antagonists
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2006079076A3 (en) Yersinia spp. polypeptides and methods of use
WO2005118831A3 (en) Polymeric compositions and related methods of use
NO20075140L (en) Methods and Preparations for Modulating Vascular Integrity
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2007075852A3 (en) Calcium channel antagonists
WO2005107461A3 (en) Modulating lymphatic function
WO2005054495A3 (en) Ligand-containing micelles and uses thereof
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
WO2005074645A3 (en) Methods and compositions for modulating angiogenesis
WO2004093892A3 (en) Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
WO2006029398A3 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
WO2006014669A3 (en) Methods and compositions for treatment of intraepithelial neoplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11572349

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11572349

Country of ref document: US